## 2 Materials and Methods
### Study Groups  
Fifty-six male Wistar-Bratislava rats, weighing between 200 and 250 g were randomly divided into eight groups of seven rats/group, as follows:  
(1) Control group (C): Rats received only saline (0.09%) throughout the whole experiment, administered by gavage. On day 7, they were given an intraperitoneal citrate buffer, and on day 22 they were injected with saline (0.09%) subcutaneously.  
(2) Control group with acute myocardial infarction (AMI): Rats received only saline (0.09%) throughout the whole experiment, administered by gavage. On day 7 they received an intraperitoneal citrate buffer, and on day 22 they were given ISO at a dose of 45 mg/Kg bw subcutaneously to induce AMI.  
(3) Diabetic rats control group (T1 DM): Rats received only saline (0.09%) throughout the whole experiment, administered by gavage. On day 7, they received 65 mg/Kg bw of intraperitoneal STZ for T1 DM induction and on day 22 they were injected with saline (0.09%) subcutaneously.  
(4) Control group with diabetic rats and acute myocardial infarction (T1 DM-AMI): Rats received only saline (0.09%) throughout the whole experiment, administered by gavage. On day 7, they received 65 mg/Kg bw of intraperitoneal STZ to induce T1 DM, and on day 22 they were injected with ISO at a dose of 45 mg/Kg bw subcutaneously to induce AMI.  
(5) Group of diabetic rats pretreated with saline (0.09%), treated with curcumin and induced AMI (S-T1 DM-CC-AMI): Rats were pretreated with saline (0.09%) for 7 days, administered by gavage. On the 7 th day, they received 65 mg/Kg bw of intraperitoneal STZ for the induction of T1 DM, in the next 15 days they were treated with curcumin solution in a dose of 200 mg/Kg bw administered by gavage, and on the 22 nd day they were injected with ISO at a dose of 45 mg/Kg bw subcutaneously in order to induce AMI.  
(6) Group of diabetic rats pretreated and treated with curcumin and induced AMI infarction (CC-T1 DM-CC-AMI): Rats were pretreated with curcumin solution at a dose of 200 mg/Kg bw for 7 days administered by gavage. On day 7, they received 65 mg/Kg bw of intraperitoneal STZ for T1 DM induction, in the next 15 days they were treated with curcumin solution at a dose of 200 mg/Kg bw administered by gavage, and on day 22 they were injected with ISO at a dose of 45 mg/Kg bw subcutaneously in order to induce AMI.  
(7) Group of diabetic rats pretreated with saline (0.09%), treated with curcumin nanoparticles and induced AMI (S-T1 DM-NC-AMI): Rats were pretreated with saline (0.09%) for 7 days administered by gavage. On day 7, they received 65 mg/Kg bw of intraperitoneal STZ for the induction of T1 DM, in the next 15 days they were treated with a solution of curcumin nanoparticles at a dose of 200 mg/Kg bw administered by gavage, and on day 22 were injected with ISO at a dose of 45 mg/Kg bw subcutaneously in order to induce AMI.  
(8) Group of diabetic rats pretreated and treated with curcumin nanoparticles and induced AMI (NC-T1 DM-NC-AMI): Rats were pretreated with curcumin solution at a dose of 200 mg/Kg bw time for 7 days administered by gavage. On day 7, they received 65 mg/Kg bw of intraperitoneal STZ for inducing T1 DM, in the next 15 days they were treated with a solution of curcumin nanoparticles at a dose of 200 mg/Kg bw administered by gavage, and on day 22 they were injected with ISO at a dose of 45 mg/Kg bw subcutaneously in order to induce AMI.  
Figure 1 is a summary of the experimental groups involved in this study.